Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19961355 | 0.83 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL19961344 | 0.80 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL19961332 | 0.79 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL19961314 | 0.78 | ALDH1A1 (0.67) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL19961306 | 0.76 | RAB9A (0.69) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL7301191 | 0.75 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL7301194 | 0.75 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL19961316 | 0.74 | RAB9A (0.73) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL19961309 | 0.73 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1MAPTHPGD | |
| SCHEMBL692258 | 0.72 | MEN1 (0.90) | RAB9ASMN1; SMN2NPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NOVALEX THERAPEUTICS INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NOVALEX THERAPEUTICS INC (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | FAR1, TECR, ECI1 | RAB9A 1863/4885SMN1; SMN2 1359/4885NPC1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.